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Sotos syndrome is an autosomal dominant condition characterized
by overgrowth resulting in tall stature and macrocephaly, together
with an increased risk of tumorigenesis. The disease is caused by
loss-of-function mutations and deletions of the nuclear receptor
SET domain containing protein-1 (NSD1) gene, which encodes a
histone methyltransferase involved in chromatin regulation. How-
ever, despite its causal role in Sotos syndrome and the typical
accelerated growth of these patients, little is known about the
putative contribution of NSD1 to human sporadic malignancies.
Here, we report that NSD1 function is abrogated in human neu-
roblastoma and glioma cells by transcriptional silencing associated
with CpG island-promoter hypermethylation. We also demonstrate
that the epigenetic inactivation of NSD1 in transformed cells leads
to the specifically diminished methylation of the histone lysine
residues H4-K20 and H3-K36. The described phenotype is also
observed in Sotos syndrome patients with NSD1 genetic disrup-
tion. Expression microarray data from NSD1-depleted cells, fol-
lowed by ChIP analysis, revealed that the oncogene MEIS1 is one
of the main NSD1 targets in neuroblastoma. Furthermore, we show
that the restoration of NSD1 expression induces tumor suppressor-
like features, such as reduced colony formation density and inhi-
bition of cellular growth. Screening a large collection of different
tumor types revealed that NSD1 CpG island hypermethylation was
a common event in neuroblastomas and gliomas. Most impor-
tantly, NSD1 hypermethylation was a predictor of poor outcome in
high-risk neuroblastoma. These findings highlight the importance
of NSD1 epigenetic inactivation in neuroblastoma and glioma that
leads to a disrupted histone methylation landscape and might have
a translational value as a prognostic marker.
cancer  DNA methylation  epigenetics  histone  overgrowth
Sotos syndrome is an autosomal dominant condition character-ized by physical overgrowth during the first years of life, a
distinctive facial appearance, and learning disability (1, 2) with an
increased incidence of malignant neoplasms (1–4). The distinctive
head shape and size has led to Sotos syndrome sometimes being
called cerebral gigantism (1, 2). Mutations in the nuclear receptor
SET [su(var)3–9, enhancer-of-zeste, trithorax] domain containing
protein-1 (NSD1) gene are found in patients exhibiting the clinical
symptoms of Sotos syndrome (1, 2, 5). There are occasional
individuals with NSD1 defects that overlap clinically with Sotos
syndrome and other conditions such as Weaver syndrome (6, 7).
The vast majority of NSD1 mutational mechanisms, including
truncating, missense, and splice-site mutations and deletions, result
in loss of function of the NSD1 protein (1, 2).
The NSD1 protein contains a SET domain and other functional
domains, including plant homeodomain and proline-tryptophan-
tryptophan-proline domains, both of which are involved in a
protein–protein interaction (8). NSD1 has histone methyltrans-
ferase activity, demonstrated by the use of a recombinant protein-
containing SET domain of NSD1 that has the ability to methylate
the histone lysine residues H3-K36 and H4-K20 (9) and in the
context of leukemia cells within the fusion proteinNUP98-NSD1 to
methylate H3-K36 in association with gene activation (10). There
is growing evidence that deregulation of SET domain-containing
proteins, such as NSD1, has an important role in cellular transfor-
mation (11), with the leukemia-translocated H3-K4 and H3-K36
histone methyltransferases hDOT1L and MLL, respectively, being
further examples (12, 13). The case for NSD1 is even more
interesting because its genetic disruption in Sotos syndrome is
associated with an elevated risk of cancer (1–4), as occurs with
other childhood overgrowth conditions such as Beckwith-
Wiedemann (14). Because patients with NSD1 germ-line genetic
disruption have an increased risk of developing malignancy before
adulthood, including neuroblastoma, Wilms tumors, and hemato-
logical malignancies, a tumor-suppressor function for NSD1 might
be proposed. This putative role is also supported by the presence of
genomic rearrangements involving NSD1 in leukemias (10, 15) and
breast cancer cells (16). However, somatic mutations of NSD1 have
not been described in sporadic neoplasms. Transcriptional inacti-
vation by cytosine/phosphate/guanine (CpG) island promoter hy-
permethylation is an alternative mechanism for the inactivation of
tumor suppressor genes (17–19). Similar scenarios to that outlined
for NSD1 have been described for familial tumor-suppressor genes,
such as hMLH1 and BRCA1, which are very rarely mutated in
sporadic tumors, but undergo epigenetic inactivation in noninher-
ited neoplasms (17–19).
Here, we demonstrate that NSD1 undergoes CpG island pro-
moter methylation-associated gene silencing in human neuroblas-
toma and glioma cells. NSD1 epigenetic inactivation is associated
with global diminished levels of trimethylated histone lysine resi-
dues H4-K20 andH3-K36, and NSD1 protein absence in the 5 end
regulatory of its target genes, such as the oncogene MEIS1.
Furthermore, the reintroduction of NSD1 reduces colony forma-
tion and cell growth, supporting a tumor-suppressor role. Most
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important, the presence of aberrant methylation at the NSD1
promoter predicts worse survival in high-risk neuroblastoma
patients.
Results
NSD1 Promoter CpG Island Hypermethylation Leads to Gene Inacti-
vation. NSD1 is a gene candidate for hypermethylation-associated
inactivation in human cancer because a 5-CpG island is located
around the transcription start site (Fig. 1A). To analyze the DNA
methylation status of the promoter-associated CpG island, we
screened 72 human cancer cell lines from 12 different cell malig-
nancy types (Table S1), using bisulfite genomic sequencing and
methylation-specific PCR targeted to the area surrounding the
transcription start site. NSD1 CpG island promoter hypermethyl-
ation was found in three cancer cell lines: LAI-5S (neuroblastoma),
LAN-I (neuroblastoma), and U373-MG (glioblastoma) (Fig. 1 A
and B). All normal tissues analyzed, including lymphocytes and
brain, were completely unmethylated at the NSD1 promoter (Fig.
1A andB).Genomic sequencing of theNSD1 gene in unmethylated
neuroblastomas and gliomas cell lines did not reveal any mutation
(Fig. S1).
Having noted NSD1 promoter hypermethylation in cancer cell
lines, we assessed the association between this epigenetic aberration
and the putative transcriptional inactivation of the NSD1 gene at
the RNA and protein levels. The cancer cell lines LAI-5S, LAN-I,
and U373-MG, hypermethylated at the NSD1 CpG island, had
minimal expression of the NSD1RNA transcript, as determined by
RT-PCR (Fig. 1C) and NSD1 protein, as determined by Western
blot analysis (Fig. 1D) and immunofluorescence (Fig. 1E). In
contrast, SK-N-JD and SK-N-BE(2)C, two neuroblastoma cells
lines unmethylated at the NSD1 promoter, expressed NSD1 RNA
and protein (Fig. 1 C–E). We established a further link between
NSD1 CpG island hypermethylation and its gene silencing by
treating the methylated cell lines with a DNA demethylating agent.
The treatment of the LAI-5S, LAI-55N, LAN-I, andU373-MG cell
lines with the demethylating drug 5-aza-2-deoxycytidine re-
stored the expression of NSD1 RNA transcript and protein (Fig.
1 C and D).
NSD1 Epigenetic Silencing in Cancer Cells Is Associated with Dimin-
ished Trimethylated-K20-H4 and Trimethylated-K36-H3. We next ex-
amined whether the loss of the NSD1 transcript by 5-CpG island
hypermethylation affected its histone residuemarks, methylation of
the histone lysine residues H3-K36 and H4-K20 (9, 10). Using
Western blot analysis, immunofluorescence, and high-performance
capillary electrophoresis, we observed reduced levels of trimethy-
lated H3-K36 andH4-K20 in LAI-5S and LAN-1 cells (Fig. 2A and
Fig. S1), all of them hypermethylated at the NSD1 promoter,
compared with SK-N-BE(2)C and SK-N-JD cells (Fig. 2A and Fig.
S1), the latter two having an unmethylated NSD1 promoter.
Interestingly, the levels of dimethylated forms of H3-K36 and
H4-K20 were similar in cancer cells with hypermethylated or
unmethylated NSD1 CpG islands (Fig. S2), suggesting a more
prominent role for NSD1 in establishing the trimethylated histone
lysines residues. To reinforce the concept that NSD1 was the
enzyme mainly responsible for the described histone trimethylated
marks in our tumoral context, we analyzed the expression levels of
other histone methyltransferases targeting these particular lysines,
such as SET2 (HYPB/HIF-1, KMT3A) and SMYD2 (KMT3C),
which specifically methylate H3-K36 (20, 21), and Pr-SET7/8
(KMT5A) and SUV4–20h1,h2 (KMT5B,C), which have been
implicated in the monomethylation and trimethylation of H4-K20
(22, 23). We observed similar expression of these four enzymes in
cancer cells with hypermethylated and unmethylated NSD1 (Fig.
2B), strengthening the evidence for the function of NSD1 in the
described histone modifications. Furthermore, we extended the
analyses of the trimethylated H3-K36 and H4-K20 forms to lym-
phoblastoid cell lines obtained from Sotos syndrome patients to
determine whether they recapitulate the diminished levels of these
marks observed in NSD1 epigenetically silenced cancer cells. The
assessment of seven Sotos syndrome samples carrying different
inactivating genetic disruptions of NSD1 showed that these patients
indeed had significantly decreased trimethylated H3-K36 and H4-
K20 (Fig. 2C and Fig. S1) compared with lymphoblastoid cell lines
from healthy donors, again supporting a central role for NSD1 in
the formation of the aforementioned trimethylated lysine residues.
Loss of NSD1 Recruitment to 5-Regulatory Regions of Growth-
Promoting Genes in Hypermethylated Cancer Cells: The Example of the
MEIS1 Oncogene in Neuroblastoma. The divalent specificity to meth-
ylate H4-K20 and H3-K36 in vitro (9) is currently thought to be
unique to NSD1, and our findings indicate that there is also double
substrate specificity in vivo. H4-K20 methylation appears to be
associated with transcriptional silencing (23, 24) and H3-K36
methylation has been found primarily in active genes throughout
the gene body (25, 26), but it also might also be present in
inactivated genes, in particular cellular contexts and genome loci
(27). NSD1 is also implicated in transcriptional repression through
its interaction with NIZP1, a zinc finger protein that interacts with
the C5HCH domain of NSD1 and represses transcription in an
NSD1-dependent fashion (28). Thus, it is possible that abrogation
of NSD1-mediated repression of growth-promoting genes might
contribute to human tumorigenesis.
To identify NSD1 target genes that might fit this candidate
criterion, we used an RNA interference approach to deplete NSD1
expression in an unmethylated-expressing neuroblastoma cell line
(SK-N-JD) (Fig. 3A) followed by expression microarray hybridiza-
tion (GeneChip Human Genome U133 Plus 2.0 Array). The
depletion of NSD1 expression was associated with lower cellular
levels of the NSD1-related histone marks: trimethylated-K20-H4
and trimethylated-K36-H3 (Fig. 3A). The analysis of the expression
microarray data fromNSD1-depleted SK-N-JD cells demonstrated
that 154 genes underwent a2-fold change.Most of them [94 genes
(61%)] underwent2-fold up-regulation (Table S2) and 60 (39%)
underwent2-fold down-regulation (Table S2). Most importantly,
among the up-regulated genes, one of the highest scorers with a
fold-change value of 21.11 (Table S2) was the MEIS1 oncogene, a
critical growth-promoting factor in neuroblastoma (29, 30).
Once we also confirmed the high up-regulation of the MEIS1
transcript upon NSD1 depletion by single quantitative RT-PCR
(Fig. 3B), we performed conventional and quantitative ChIP for
NSD1 occupancy at the 5 regulatory region of the MEIS1 onco-
gene. We observed that the NSD1 protein was absent from the
MEIS1 promoter region of NSD1 epigenetically silenced neuro-
blastoma cells, such as LAI-5S (Fig. 3C), but it did occupy the 5 end
regulatory region of MEIS1 in NSD1-expressing neuroblastoma
cells, such as SK-N-JD (Fig. 3C).We also found amarkedly reduced
presence of the NSD1 protein in the MEIS1 promoter of Sotos
syndrome lymphoblastoid cells with genetic disruption of theNSD1
gene (OGS55) (Fig. 3C), reinforcing the specificity of the experi-
mental approach. Most importantly, we found that NSD1 recruit-
ment to the MEIS promoter was associated with transcriptional
repression of the MEIS1 gene (Fig. 3D), whereas neuroblastoma
cells with NSD1 CpG island hypermethylation highly expressed the
MEIS1 transcript (Fig. 3D) and protein (Fig. 3D) in associationwith
the absence of NSD1 binding to the MEIS1 promoter. In a similar
fashion, Sotos syndrome lymphoblastoid cells, which had an NSD1
genetic defect, expressed high levels of the MEIS1 transcript
compared with healthy donors (Fig. 3D). Furthermore, NSD1
epigenetic silencing (LAI-5S) and genetic loss of NSD1 (OGS55)
both are associated with a histone modification profile in the 5
region of MEIS1 characterized by an enrichment in active marks
(such as trimethyl-K4-H3) and a depletion in repressive marks
(trimethyl-K20-H4, trimethyl-K9-H3, and trimethyl-K27-H3) (Fig.
3E). In contrast, unmethylated NSD1 neuroblastoma cells (SN-N-
JD) show that NSD1 recruitment to the 5 region of MEIS1 is











associated with an enrichment in the transcriptional silencing
histone marks (trimethyl-K20-H4, trimethyl-K9-H3, and trimethyl-
K27-H3) and a depletion in the active marks (trimethyl-K4-H3)
(Fig. 3E). Only one histone mark putatively associated with tran-
scriptional activation is enriched when NSD1 is recruited to the 5
region of MEIS1 (SN-N-JD), trimethyl-K36-H3 (also catalyzed by
NSD1 as it occurs with its antagonistic silencing mark trimethyl-
K20-H4) (Fig. S2), despite the minimal expression of the MEIS1
transcript (Fig. 3D) and protein (Fig. 3D). Thus, our results suggest
that in neuroblastoma cells NSD1 promotes MEIS1 gene silencing
by its trimethyl-K20-H4 repressor activity (9) so that it occurs in the
presence of other histone marks of silencing (trimethyl-K9-H3 and
trimethyl-K27-H3) and the loss of active marks (trimethyl-K4-H3).
Together with the intriguing data derived from the trimethyl-
K36-H3 ChIP assays, our findings confirm that NSD1 is a unique
multitasked protein with a dual activity that can act as a repressor,
as in our neuroblastoma model, or as a coactivator, as in the
NUP98-NSD1 leukemia fusion protein (10), depending on the
cellular context (31). Overall, our data link NSD1 protein promoter
occupancy and the silencing of the MEIS1 oncogene and suggest
that NSD1 epigenetic inactivation is an upstream mechanism that
may well explain the observed overexpression of the MEIS1
oncogene in human neuroblastoma (30, 31).
NSD1 Has Tumor Suppressor-Like Properties in Cancer Cells. Related
to the increased risk of malignancies in Sotos syndrome patients
with NSD1 genetic disruptions (1–4) and our finding that NSD1
epigenetic silencing mediates the overexpression of the MEIS1
oncogene, we assayed the ability of NSD1 to function as a sup-
pressor of tumor growth in ourmodel, using the neuroblastoma cell
line LAI-5S with NSD1 methylation-associated silencing. We first
tested the inhibitory abilities of NSD1 in a colony-focus assay using
G418 selection after transfection with the NSD1 gene (pEGFP-
C1-NSD1) or the empty vector (pEGFP-C1). NSD1 expression was
monitored by RT-PCR (Fig. 4A). NSD1 re-expression demon-
strated tumor-suppressing activity with a reduction of 50% in
colony-formation density with respect to the empty vector (Fig.
4A). We also measured the effect of transfection of NSD1 on the
in vitro growth of LAI-5S cells using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation assay
over time (Fig. 4B). Upon restoration of NSD1 expression in the
LAI-5S hypermethylated neuroblastoma cell line, the cells proved
less viable in the MTT assay (Fig. 4B). Because neuroblastoma is
a tumor type where differentiation drugs, such as retinoic acid
derivatives, have shown efficacy (32–34), we wondered whether one
mechanism underlying growth suppression upon NSD1 transfec-
tion was the induction of differentiation. Neuroblastomas are
composed of variable proportion of neuroblasts (neuronal lineage)
and Schwannian-like cells (glial lineage) and neuroblastoma cell
lines can be differentiated in these lineages (32, 33). We found that
restoration of NSD1 expression in LAI-5S hypermethylated neu-
roblastoma cells induced glial differentiation assessed by the cal-
cium binding protein S100B marker (Fig. S3), whereas neuronal
differentiation determined by the neurofilaments markers NF68
and NF200 was not observed (Fig. S3). Finally, we also studied
whether the knockdown of NSD1 expression by RNA interference
in an expressing neuroblastoma cell line unmethylated at the NSD1
5-CpG island, SK-N-JD, had growth stimulatory effects. We
observed that the depletion of NSD1 expression in SK-N-JD cells,
in which we also developed the expression microarray experiment
described above, significantly increased cell growth (Fig. 4C).
Overall, the data presented here suggest a tumor-suppressor role
for NSD1.
NSD1 CpG Island Hypermethylation in Human Primary Malignancies: A
Predictor of Poor Outcome in Neuroblastoma. After the demonstra-
tion of the epigenetic loss of function of NSD1 in cancer cell lines
and its impact on the histone modification profile and tumor
Fig. 1. Analysis of NSD1 CpG island promoter methylation status and gene
function in human cancer cell lines. (A) Schematic depiction of the NSD1 CpG
island around the transcription start site (long black arrow). CpG dinucleotides
are represented as short vertical lines. Location of bisulfite genomic sequencing
and methylation-specific PCR primers are indicated as black and white arrows,
respectively. Results of bisulfite genomic sequencing of 10 individual clones in
two regions of the NSD1 CpG island are shown. Presence of a methylated or
unmethylated cytosine is indicated by a black or white square, respectively. NL,
normal lymphocytes; NB, normal brain. (B) Methylation-specific PCR for the NSD1
gene in cancer cell lines. The presence of a PCR band under lane M indicates
methylated genes, while the presence under lane U indicates unmethylated
genes. In vitro methylated DNA (IVD) is used as positive control. (C) RT-PCR
analysis of NSD1 expression. Treatment with the demethylating agent (ADC)
reactivates NSD1 gene expression in the NSD1-hypermethylated cancer cell lines
LAI-5S, LAN-1, and U373-MG. (D) Western blot analysis of NSD1 expression. The
NSD1-hypermethylated cell lines LAI-5S and U373-MG do not express the NSD1
protein, in comparison with the unmethylated SK-N-JD and SK-N-BE(2)C cells.
Treatment with the demethylating agent (ADC) reactivates NSD1 gene expres-
sion. (E) Immunofluorescence analysis of NSD1 expression. The NSD1 CpG island
methylated cell line LAI-5S does not stain for the NSD1 protein, in comparison
with the unmethylated SK-N-JD cells. [Magnifications: 40 (LAI-5S) and 20
(SK-N-JD).]
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growth, we assessed the prevalence of NSD1 CpG island promoter
hypermethylation in cancer patients. We examined 377 human
primary tumors corresponding to five different tissue types and
observed an identical pattern with respect to the tumor type as that
seen in the cancer cell lines. NSD1 CpG island hypermethylation
was observed in primary neuroblastomas (37.9%, 69/182) and
gliomas (11.1%, 8/72), but it was absent in other tumor types such
as colon (0/49), breast (0/25), acute lymphocytic leukemia (0/34),
and acute myelocytic leukemia (0/15) (Fig. 5A). NSD1 methylation
status was confirmed by bisulfite genomic sequencing in 10 cases of
primary neuroblastoma (five hypermethylated and five unmethyl-
ated) (Fig. S4). The presence of NSD1 CpG island hypermethyl-
ation in neuroblastomas was not associated with the methylation
status of the described CpG island methylator phenotype (CIMP)
targets in this tumor type (35–37), such asRASSF1A (Kendall’s tau
b test, P  0.948), BLU (P  0.681), PCDHG4C4 (P  0.292), or
CRYBA2 (P  0.519) (Fig. S5). Most importantly, we observed
that the presence of NSD1 hypermethylation in primary human
neuroblastomas was associated with lower levels of the NSD1
transcript (Kendall’s tau-b test, reverse correlation coefficient r 
Fig. 2. Histone modifications and histone modifiers
according to NSD1 status. (A) Western blot and immuno-
fluorescence analysis of 3Me-K20-H4 and 3Me-K36-H3 in
neuroblastoma cells. The NSD1-hypermethylated cell
lines LAI-5S and LAN-1 show reduced levels of the 3Me-
K20-H4 and 3Me-K36-H3 marks, in comparison with the
unmethylated SK-N-BE(2)C and SK-N-JD cells. (Magnifi-
cation: 40.) (B) Western blot analysis of the histone
modifiers SET2 and SMYD2 (methylation of H3-K36) and
Pr-SET7/8 and SUV4–20h1,h2 (methylation of H4-K20)
show similar expression with independence of the NSD1
epigenetic inactivation status. (C) Western blot analysis
of 3Me-K20-H4 and 3Me-K36-H3 in Sotos syndrome sam-
ples. The lymphoblastoid cell lines from seven Sotos syn-
drome patients (R604X to OGS661) show reduced levels
of the 3Me-K20-H4 and 3Me-K36-H3 marks, in compari-
son with unmethylated SK-N-JD neuroblastoma cells or
lymphoblastoid cell lines from healthy donors (CCL256.1
and GMO8729).
Fig. 3. Loss of NSD1 recruitment to the 5 end of the
MEIS1 oncogene in neuroblastoma. (A) (Left) NSD1 de-
pletion by RNA interference in SK-N-JD cells is associated
with reduced levels of 3Me-K20-H4 and 3Me-K36-H3.
(Right) NSD1 expression upon RNA interference moni-
tored by RT-PCR in CpG island unmethylated SK-N-JD
cells. (B) Quantitative RT-PCR shows the high up-
regulation of the MEIS1 transcript upon NSD1 depletion.
(C) Determination by conventional and quantitative
ChIPofNSD1occupancyat the5endpromoter regionof
the MEIS1 gene. The presence of the NSD1 protein is
evident in unmethylated neuroblastoma cells (SK-N-JD)
and lymphoblastoid cells derived from healthy donors
(GMO8729), whereas it is absent or extremely dimin-
ished in neuroblastoma cells with NSD1 epigenetic inac-
tivation (LAI-5S) and lymphoblastoid cells from a Sotos
syndrome patient (OGS55). (D) Quantitative RT-PCR and
Western blot analysis shows the high up-regulation of
the MEIS1 transcript in neuroblastoma cells with NSD1
CpG island hypermethylation (LAI-5S and LAN-1) com-
pared with NSD1 unmethylated cells (SK-N-JD and SK-
N-BE (2)C) (Left) and in Sotos syndrome lymphoblastoid
cells (OGS55 to R2017W) compared with lymphoblastoid
cells from healthy donors (CCL256.1 and GMO8729)
(Right). (E) Quantitative ChIP for histone modification
marks at the 5 end of the MEIS1 gene. NSD1 epigenetic
silencing (LAI-5S) and genetic loss (OGS55) both are as-
sociated with a depletion in repressive marks (3Me-K20-
H4, 3Me-K9-H3 and 3Me-K27-H3) and an enrichment in
active marks (3Me-K4-H3) compared with the NSD1 un-
methylated SK-N-JD cells.











0.2368, P  0.0423) (Fig. S5) using our generated mRNA
expression microarray data (38).
Because of the substantial frequency of NSD1 hypermethylation
observed in neuroblastomas, the most common extracranial solid
cancer diagnosed during infancy and childhood (32) and with a
mortality that approaches 30–60% overall (33), we wondered
whether it had a correlation with clinicopathological andmolecular
features. We did not observe any association between NSD1
hypermethylation and age at diagnosis, clinical stage, age at death,
presence of MYCN amplification, and loss of heterozygosity at the
chromosomic regions 1p36, 1p22, 11q, 14q, 9p, 19q, and 17q G
(Table S3). However, we found that the presence of hypermethyl-
ation of the NSD1 promoter influenced the survival of these
patients. Of the 39 samples with gene hypermethylation, 17 (43.6%)
were from surviving patients and 22 (56.4%) corresponded to
deceased patients, whereas for the group of cases with the unmeth-
ylated gene, 41 (62.1%) cases survived and 25 (37.9%) died of the
disease. The differences in these relative proportions were statis-
tically significant (Fisher’s exact test, P 0.015), suggesting that the
likelihood of death from disease was significantly higher in the
group of tumors with NSD1 promoter hypermethylation. When all
cases were considered, the Kaplan–Meier survival analysis carried
out on hypermethylated and unmethylated tumor samples showed
a nonsignificant trend for lower survival in the group of samples
with a hypermethylated NSD1 gene (P  0.05). However, the
Kaplan–Meier survival analysis carried out on specific risk groups
(Fig. 5B) demonstrated that NSD1 hypermethylation is a predictor
of poor outcome in high-risk neuroblastoma, but not in low- or
intermediate-risk neuroblastoma. In fact, the group of samples with
NSD1 promoter hypermethylation showed significantly lower over-
all survival (P  0.048) and progression-free survival (P  0.026)
than did the unmethylated samples. Thus, we can conclude that
CpG island hypermethylation of the histone methyltransferase
NSD1 is a significant predictor of poor outcome in high-risk
neuroblastoma. This finding may be clinically relevant in the
management of these patients.
Discussion
Overgrowth syndromes encompass a heterogeneous group of dis-
orders that involve global, regional, or localized areas of excess
growth relative to another part of the body or the age-related peer
group. One striking feature of overgrowth syndromes is the risk of
tumorigenesis (3, 4), but little is known about the potential contri-
bution of the overgrowth-linked disease genes to sporadic human
tumors. Herein, we show that epigenetic silencing of the NSD1
gene, responsible for the overgrowth Sotos syndrome, contributes
to the development of nonhereditary neuroblastoma and glioma.
These data match with the observation that in Sotos syndrome
patients, who carry NSD1 genetic disruptions, there is a distinctive
increased incidence of neural crest tumors, including neuroblas-
toma and glioma (3, 4).
The DNA methylation-associated loss of NSD1 in neuroblas-
toma and glioma provides double proof of the contribution of
epigenetic alterations to human tumorigenesis, first by the lesion
itself, the DNA hypermethylation event at the 5 regulatory region
of the gene, and second by the affected target gene, because NSD1
encodes a histone methyltransferase. Thus, NSD1 CpG island
hypermethylation increases the growing body of data showing that
the disruption of epigenetic genes is a common finding in human
cancer. Illustrative examples are provided by the translocations of
the histone methyltransferases MLL1 and hDOT1L (12, 13) or the
mutations in the histone H3-K27 demethylase UTX (39) or the
Fig. 4. Tumor suppressor-like properties of NSD1. (A) Colony formation assay.
(Left) NSD1 expression monitored by RT-PCR and Western blot analysis in empty
vector and NSD1-transfected LAI-5S cells and densitometric quantification of the
colonyformationdensity. (Right) Examplesof thecolonyfocusassayafter2-week
selection with G418 and methylene blue staining. (B) A decrease of cell viability
over time, determined by the MTT assay, upon NSD1 transfection is observed. (C)
Effect of NSD1 depletion on cell growth in the NSD1 unmethylated SK-N-JD
neuroblastoma cells. (Left) An increase of cell viability over time, determined by
the MTT assay, upon NSD1 depletion is observed. (Right) Optical image of the
effect of NSD1 reduction on the in vitro growth of SK-N-JD cells at 48 h. (Mag-
nification: 10.)
Fig. 5. NSD1 CpG island hypermethylation in primary human malignancies. (A)
Analysis of NSD1 methylation by methylation-specific PCR. The presence of a PCR
bandunder laneMindicatesmethylatedgenes,whereas thepresenceunder lane
U indicates unmethylated genes. Normal lymphocytes (NL) and in vitro methyl-
ated DNA (IVD) are used as negative and positive control for unmethylated and
methylated genes, respectively. NSD1 hypermethylation is observed in primary
neuroblastomas (N1-N6) and gliomas (G1-G6), but it was absent in other tumor
types (example, colorectal cancer,CRC1-CRC6). (B)Kaplan–MeieranalysisofNSD1
promoter hypermethylation in neuroblastoma patients. NSD1 promoter hyper-
methylation was significantly associated with lower overall survival (P  0.048)
and progression-free survival (P 0.026).
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microRNA processing machinery gene TARBP2 (40). In the case
of NSD1, other SET2 family members such as NSD2 and NSD3
have also been reported to be genetically altered in cancer (11).
It is worth noting that before its identification as the gene for the
Sotos syndrome NSD1 was already implicated in malignancy as a
fusion partner for the NUP98 gene in childhood acute myeloid
leukemia (AML) (10, 15). It is likely that the mechanism by which
NSD1 contributes to AML differs from that controlling its tumor-
igenic role in Sotos syndromepatients and sporadic neuroblastomas
and gliomas, because the NUP98-NSD1 fusion protein contains
exons 6–23 that include almost all of the functional domains of
NSD1 (41). AML does not occur more frequently in Sotos syn-
drome (3), and we have not found any leukemia with NSD1 CpG
island hypermethylation. In addition, the NUP98-NSD1 fusion
protein has been associatedwith gene activation (10), whilewe show
at a candidate gene and global genomic level that NSD1 epigenetic
silencing is linked to the activation of oncogenes, such as the
paradigmatic case of MEIS1 in neuroblastoma. These data imply
that NSD1 is a versatile protein that can act as a corepressor or
coactivator, depending on the cellular context (31). Furthermore, it
is worth noting that the loss of the trimethyl-K20-H4 enzymatic
activity of NSD1 by its epigenetic silencing might explain, in the
context of neuroblastoma and glioma, the commonly observed
reduced levels of this histone mark in tumorigenesis (42).
Overall, our results demonstrate that epigenetic silencing of the
histone methyltransferase NSD1 by promoter CpG island hyper-
methylation contributes to human cancer, provides a link between
the loss of its histone methylation enzymatic activity and the
activation of oncogenes, and supports the concept that the disrup-
tion of genes involved in overgrowth syndromes can also be relevant
in the development of human sporadic tumors. Finally, these
observations could have therapeutic implications because NSD1
DNA methylation-associated silencing is associated with poor
outcomeand there are now clinically approvedDNAdemethylating
agents thatmay be able to restoreNSD1 functionality with potential
tumor growth inhibitory effects.
Materials and Methods
Full details are provided in SI Text. Briefly, DNA methylation status was
established by PCR analysis of bisulfite-modified genomic DNA; NSD1 and
MEIS1 expression was determined by semiquantitative RT-PCR, quantitative
RT-PCR, and Western blot and immunolocalization analysis. NSD1 transfection
was performed by electroporation and NSD1 knockdown by RNA interfer-
ence. ChIP, colony formation, and cell viability assays were performed as
described (40).
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